Cognitive impairment in patients with Parkinson's disease is gaining increased clinical
significance owing to the relative success of therapeutic approaches to the motor symptoms …

Background. Cholinesterases are a group of serine hydrolases that split the neurotransmitter
acetylcholine (ACh) and terminate its action. Of the two types, butyrylcholinesterase and …

Alzheimer's disease (AD) is characterized by a progressive phenotypic downregulation of
markers within cholinergic basal forebrain (CBF) neurons, frank CBF cell loss and reduced …

Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition
with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD) …

Like acetylcholinesterase, butyrylcholinesterase (BChE) inactivates the neurotransmitter
acetylcholine (ACh) and is hence a viable therapeutic target in Alzheimer's disease, which is …

This review examines the large body of toxicological and epidemiological information on
human exposures to chlorpyrifos, with an emphasis on the controversial potential for …

Abstract The cholinesterase inhibitors (ChE-Is) attenuate the cholinergic deficit underlying
the cognitive and neuropsychiatric dysfunctions in patients with AD. Inhibition of brain …

Objective: To examine the role of butyrylcholinesterase (BuChE) in cholinergic signaling and
neurologic conditions, such as Alzheimer's disease (AD). The rationale for inhibiting …

Butyrylcholinesterase (BChE) is regarded as a promising drug target as its levels and activity
significantly increase in the late stages of Alzheimer's disease. To discover novel BChE …

Objective To assess the effect of rivastigmine in patients with mild cognitive impairment
(MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive …